Table 2

Allelic association of SNPs in the TIE2 gene with nAMD and PCV in the Hong Kong cohort

	SNP	Nucleotide change	Minor allele	MAF			Allelic association
				nAMD	PCV	Ctrl	nAMD-ctrl		PCV-ctrl		nAMD+PCV-ctrl
				nAMD	PCV	Ctrl	P values	OR (95% CI)	P values	OR (95% CI)	P values	OR (95% CI)
1	rs615375	c.52+2671G>T	T	0.436	0.438	0.468	0.27	0.88 (0.70 to 1.10)	0.31	0.89 (0.71 to 1.11)	0.20	0.88 (0.73 to 1.07)
2	rs621786	c.52+9167A>G	A	0.250	0.266	0.273	0.36	0.89 (0.69 to 1.15)	0.78	0.96 (0.75 to 1.24)	0.47	0.93 (0.75 to 1.14)
3	rs652010	c.52+13 585G>A	G	0.447	0.464	0.492	0.12	0.83 (0.67 to 1.05)	0.33	0.89 (0.71 to 1.12)	0.12	0.86 (0.72 to 1.04)
4	rs17761403	c.52+13 708G>C	C	0.297	0.328	0.337	0.14	0.83 (0.65 to 1.06)	0.73	0.96 (0.75 to 1.22)	0.27	0.89 (0.73 to 1.09)
5	rs625767	c.53–22116C>T	C	0.350	0.359	0.419	0.014	0.75 (0.59 to 0.94)	0.035	0.78 (0.62 to 0.98)	0.0054	0.76 (0.63 to 0.92)
6	rs669441	c.53–20587C>T	C	0.343	0.352	0.389	0.095	0.82 (0.65 to 1.04)	0.18	0.85 (0.68 to 1.08)	0.066	0.84 (0.69 to 1.01)
7	rs7034505	c.53–6435G>A	G	0.451	0.408	0.416	0.22	1.15 (0.92 to 1.45)	0.77	0.97 (0.77 to 1.22)	0.57	1.06 (0.88 to 1.27)
8	rs7034591	c.53-6137A>G	G	0.323	0.338	0.316	0.80	1.03 (0.81 to 1.31)	0.42	1.10 (0.87 to 1.41)	0.52	1.07 (0.88 to 1.30)
9	rs664461	c.53–5521T>C	C	0.353	0.393	0.349	0.91	1.01 (0.80 to 1.28)	0.11	1.21 (0.96 to 1.52)	0.30	1.11 (0.91 to 1.34)
10	rs538679	c.53–5105C>A	A	0.319	0.372	0.327	0.77	0.96 (0.76 to 1.23)	0.10	1.22 (0.96 to 1.54)	0.40	1.09 (0.89 to 1.32)
11	rs504947	c.53–834G>C	C	0.249	0.281	0.268	0.45	0.90 (0.70 to 1.17)	0.61	1.07 (0.83 to 1.38)	0.88	0.98 (0.80 to 1.21)
12	rs1413825	c.364+3671A>G	G	0.367	0.361	0.326	0.13	1.20 (0.95 to 1.52)	0.20	1.17 (0.92 to 1.48)	0.09	1.19 (0.97 to 1.44)
13	rs911599	c.365-3375A>G	A	0.428	0.417	0.411	0.55	1.07 (0.85 to 1.35)	0.83	1.03 (0.82 to 1.29)	0.62	1.05 (0.87 to 1.26)
14	rs3818283	c.476-351A>G	A	0.316	0.311	0.326	0.73	0.96 (0.75 to 1.22)	0.58	0.93 (0.73 to 1.19)	0.58	0.95 (0.78 to 1.15)
15	rs3739542	c.760+93C>A	C	0.423	0.387	0.429	0.82	0.97 (0.78 to 1.22)	0.14	0.84 (0.67 to 1.06)	0.30	0.91 (0.75 to 1.09)
16	rs3824410	c.761–158G>T	T	0.410	0.468	0.436	0.36	0.90 (0.72 to 1.13)	0.27	1.14 (0.91 to 1.42)	0.91	1.01 (0.84 to 1.22)
17	rs666478	c.761–40C>T	T	0.280	0.237	0.283	0.90	0.98 (0.77 to 1.27)	0.07	0.79 (0.61 to 1.02)	0.24	0.88 (0.72 to 1.09)
18	rs10967760	c.1031-632A>G	G	0.239	0.252	0.285	0.07	0.79 (0.61 to 1.02)	0.20	0.85 (0.66 to 1.09)	0.06	0.82 (0.66 to 1.01)
19	rs2152065	c.1328-1696A>G	G	0.357	0.348	0.358	0.97	1.00 (0.79 to 1.26)	0.71	0.96 (0.76 to 1.21)	0.81	0.98 (0.80 to 1.19)
20	rs481294	c.1489+202C>T	T	0.464	0.434	0.446	0.52	1.08 (0.86 to 1.35)	0.68	0.95 (0.76 to 1.20)	0.89	1.01 (0.84 to 1.22)
21	rs3780317	c.1489+304C>T	T	0.185	0.176	0.188	0.91	0.98 (0.74 to 1.31)	0.60	0.93 (0.69 to 1.24)	0.70	0.95 (0.75 to 1.21)
22	rs549099	c.1624+2077G>C	C	0.438	0.394	0.431	0.80	1.03 (0.82 to 1.29)	0.20	0.86 (0.68 to 1.08)	0.53	0.94 (0.78 to 1.14)
23	rs606342	c.1909+76G>T	T	0.360	0.337	0.370	0.71	0.96 (0.76 to 1.21)	0.24	0.87 (0.68 to 1.10)	0.35	0.91 (0.75 to 1.11)
24	rs639225	c.1962A>G	G	0.366	0.333	0.380	0.62	0.94 (0.75 to 1.19)	0.09	0.82 (0.64 to 1.04)	0.19	0.88 (0.73 to 1.07)
25	rs1413828	c.2210–734T>C	C	0.251	0.256	0.274	0.36	0.89 (0.69 to 1.15)	0.48	0.91 (0.71 to 1.18)	0.32	0.90 (0.73 to 1.11)
26	rs3737188	c.2976T>C	C	0.179	0.150	0.174	0.82	1.04 (0.77 to 1.39)	0.26	0.84 (0.61 to 1.14)	0.59	0.93 (0.73 to 1.20)
27	rs534129	c.2991+1124A>G	G	0.238	0.256	0.267	0.25	0.86 (0.66 to 1.12)	0.68	0.95 (0.73 to 1.22)	0.34	0.9 (0.73 to 1.12)
28	rs2756901	c.3062+297T>C	T	0.172	0.174	0.187	0.51	0.91 (0.68 to 1.22)	0.56	0.92 (0.68 to 1.23)	0.45	0.91 (0.72 to 1.16)
29	rs2273717	c.3201-182A>G	A	0.227	0.248	0.197	0.20	1.20 (0.91 to 1.57)	0.03	1.35 (1.03 to 1.76)	0.038	1.27 (1.01 to 1.59)
30	rs1014049	c.3300+200C>T	T	0.326	0.303	0.313	0.63	1.06 (0.83 to 1.35)	0.71	0.95 (0.75 to 1.22)	0.95	1.01 (0.82 to 1.23)

ctrl, control; MAF, minor allele frequency; nAMD, neovascular age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; SNP, single-nucleotide polymorphism.